Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management

Related Experiment Video

Updated: Oct 1, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

E Leitersdorf1

  • 1Centre for Research, Prevention, and Treatment of Atherosclerosis, Hadassah University Hospital, Jerusalem, Israel.

International Journal of Clinical Practice
|April 3, 2002
PubMed

Insights

Many Europeans have coronary heart disease (CHD) risk factors and undertreated high cholesterol. Optimal statin doses are rarely used, but ezetimibe offers a beneficial alternative for lowering LDL-C.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Coronary heart disease (CHD) remains a significant public health concern in Europe.
  • Many individuals possess risk factors for CHD, yet treatment compliance is suboptimal.
  • Guidelines recommend low-density lipoprotein cholesterol (LDL-C) reduction, but many patients do not achieve target levels.

Purpose of the Study:

  • To highlight the challenges in hypercholesterolaemia management and LDL-C reduction in Europe.
  • To discuss the underutilization of optimal statin doses and associated barriers.
  • To introduce ezetimibe as a potential therapeutic option for lipid-modifying treatment.

Main Methods:

  • Review of current European guidelines for CHD prevention and lipid management.
  • Analysis of treatment adherence and achievement of LDL-C targets in clinical practice.
  • Evaluation of the role of statins and introduction of ezetimibe as a cholesterol absorption inhibitor.

Main Results:

  • A significant proportion of patients requiring pharmacotherapy for hypercholesterolaemia are undertreated.
  • One-third of treated patients fail to reach recommended LDL-C target levels.
  • Optimal statin doses are infrequently prescribed due to practical concerns like dosage adjustments and side effects (e.g., myalgia).

Conclusions:

  • Barriers exist in achieving optimal LDL-C reduction for CHD prevention in Europe.
  • Ezetimibe demonstrates clinical benefits in monotherapy or combination therapy for lipid modification.
  • Further strategies are needed to improve statin utilization and patient outcomes in hypercholesterolaemia management.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Lipid Digestion01:16

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.